Maturation Inhibitor Shows Promise for HIV
email article Treatment with an HIV maturation inhibitor known as GSK3640254 -- or the catchy name of GSK254 for short -- appeared to dramatically lower viral load in a proof-of-concept phase IIa clinical trial, researchers reported. In a 7-day trial that tested multiple doses of GSK254, viral loads were reduced by a factor of 50 with a dose of 140 mg and by a factor of 100 with a 200-mg dose, according to Christoph Spinner, MD, of Technical University of Munich, who presented the fin...
New York United States Josephp Mcgowan Technical University Of Munich Northwell Health Service Line Program
Source: medpagetoday.com